SQUAWK/NEWS
Account
Theme
Account
Menu
Live News NEWS FLASH L impact

Compass Therapeutics Is Maintained at Buy by Guggenheim

Ratings actions from Benzinga: GMT) Compass Therapeutics Price Target Cut to $4.00/Share From $8.00 by GuggenheimRatings actions from Benzinga

CMPX

Related stories